ArteraAI and GenesisCare Partner to Launch the First Australian-Based Clinical Trial
SAN FRANCISCO & SYDNEY–(BUSINESS WIRE)–ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tools, today announced a strategic collaborative agreement with GenesisCare, an integrated cancer care provider.
The agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools guiding treatment decisions as part of a new clinical trial.
“We are honored to be able to partner with GenesisCare to provide the clinical community in Australia a way to personalize care for their patients,” said Andre Esteva, co-founder and CEO of ArteraAI.
ArteraAI and GenesisCare share a commitment to clinical innovation and advancing precision medicine, with the aim of improving the lives of patients with localized prostate cancer.
“Our research partnership with ArteraAI aligns with our aim to offer personalized and patient-centric care in communities across Australia,” said Professor Jarad Martin, GenesisCare Radiation Oncologist.
About ArteraAI
ArteraAI is a leading precision medicine company developing AI tools to personalize cancer therapy.
ArteraAI’s multimodal artificial intelligence (MMAI) biomarker tool leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient’s clinical data. The AI combines this information to predict whether a patient will benefit from a particular therapy and determine their prognosis.
About GenesisCare Australia
GenesisCare is an integrated cancer care provider that aims to change the face of cancer care with modern treatments and techniques designed to achieve the best possible life outcomes for patients. In Australia, GenesisCare provides care to approximately 30,000 patients a year across 48 locations in metro and regional Victoria, New South Wales, Queensland, South Australia, and Western Australia. GenesisCare’s vision is to offer patients personalized, high-quality care throughout their cancer journey. For more information, visit www.genesiscare.com.
Contacts
Media:
Lesley Swiger
Antenna
artera@antennagroup.com
(202) 869-1612
Recent Posts
Esyms and DHL eCommerce partner to change medicine distribution in Malaysia
The collaboration supports Esyms's focus on medication delivery, enhancing accessibility and convenience for government hospital…
Daphne Announces 2024 Annual Results Revenue and Profit Attributable to Shareholders up 23% and 71% Respectively
Steady Final Dividend of HK$0.02 Per Share Dividend Payout Ratio was Approximately 35% (RMB' million)…
Last November was the time for EU beef in Manila, campaign led by Provacuno
MANILA, PHILIPPINES - Media OutReach Newswire - 26 March 2025 - Within the framework of…
Galaxy Macau™ and SCMP Learn Team Up to Inspire New Educational Pathways at Pioneering Parents’ Talk Held at GICC
Leading Education Experts Gather to Shape Conversations Around Global Education for the Next Generation MACAU…
Insulation Material Y-Warm: A New Era of Thin and Light Winter Apparels
BEIJING, CHINA - Media OutReach Newswire - 26 March 2025 - Even after over a…
Experience the Rich Fishing Heritage of Hong Kong with “Aberdeen 1773”
HONG KONG SAR - Media OutReach Newswire - 26 March 2025 - Hong Kong Fisherman's…